Apple: Consensus Estimates For Q2 2021

Apple (NASDAQ: AAPL) will be reporting their fiscal second quarter on April 28th after market close. Analysts have a consensus $152 12-month price target on the company, via a total of 40 analysts, with 11 analysts having strong buy ratings. 21 analysts meanwhile have buy ratings, 6 have hold ratings, one analyst has a sell rating, and one has a strong sell on the company. The street high comes from Evercore ISI with a $175 price target, and the lowest target sits at $83.

27 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 27 analysts is $76.87 billion; this number has been revised upwards from $74 billion at the start of the year. The highest revenue estimate is $83.2 billion, while the lowest is $70.9 billion.

Onto EBITDA estimates, there are currently only 10 analysts who have second-quarter EBITDA estimates. The mean is currently $22.5 billion, with this number having been revised down from $20.2 billion at the start of the year. Street high is a $23.9 billion EBITDA estimate and the lowest is $20.3 billion.

Analysts estimate that quarterly earnings per share will come in at $0.98, with this number being slightly revised up from $0.90 at the start of the year. Street high is currently $1.09 and the lowest estimate is $0.85 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

Maxar Tech: Canaccord Lifts Target To US$42 Following Elevated Profile Due To Conflict

On April 12th, Canaccord Genuity raised their 12-month price target on Maxar Technologies (TSX: MAXR)...

Sunday, April 17, 2022, 05:18:00 PM

Medipharm Labs: Canaccord Drops Target To Just $0.10

On May 16, Medipharm Labs (TSX: LABS) reported its first quarter financial results. The company...

Tuesday, May 24, 2022, 11:37:00 AM

Cronos Group: Canaccord, PI Reiterate Ratings, Adjust Revenue Estimates

Cronos Group (TSX: CRON) (NASDAQ: CRON) reported its second quarter financials on August 6 pre-market,...

Sunday, August 9, 2020, 04:20:00 PM

Haywood: TPCO Is “A Formidable California Cannabis Company with Unparalleled Consumer Reach”

Just two weeks after the de-SPACing of TPCO Holdings Corp (NEO: GRAM.u) (OTC: GRAMF), which...

Friday, January 29, 2021, 04:03:00 PM

Well Health: Canaccord Slashes Price Target To $6

On May 11th, WELL Health Technologies Corp. (TSX: WELL) reported its first quarter financial results....

Wednesday, May 25, 2022, 04:11:00 PM